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1224Objective: Metastasis is thought to be governed partially by induction of epithelial–mesenchymal transition.
Combination of proteasome and histone deacetylase inhibitors has shown significant promise, but no studies
have investigated this in esophageal cancer. This study investigated effects of vorinostat (histone deacetylase
inhibitor) and bortezomib (proteasome inhibitor) on esophageal cancer epithelial–mesenchymal transition.
Methods: Three-dimensional tumor spheroids mimicking tumor architecture were created with esophageal
squamous and adenocarcinoma cancer cells. Cells were treated with tumor necrosis factor a (to simulate
proinflammatory tumor milieu) and transforming growth factor b (cytokine critical for induction of epithelial–
mesenchymal transition). Tumor models were then treated with vorinostat, bortezomib, or both. Cytotoxic assays
assessed cell death. Messenger RNA and protein expressions of metastasis suppressor genes were assessed. After
treatment, Boyden chamber invasion assays were performed.
Results:Combined therapy resulted in 3.7-fold decrease in adenocarcinoma cell invasion (P¼ .002) and 2.8-fold
decrease in squamous cell invasion (P ¼ .003). Three-dimensional invasion assays demonstrated significant
decrease in epithelial–mesenchymal transition after combined therapy. Quantitative reverse transcriptase
polymerase chain reaction and Western blot analyses revealed robust rescue of E-cadherin transcription and
protein expression after combined therapy. Importantly, inhibition of the E-cadherin gene resulted in abolition
of the salutary benefits of combined therapy, highlighting the importance of this metastasis suppressor gene in
the epithelial–mesenchymal transition process.
Conclusions:Combined vorinostat and bortezomib therapy significantly decreased esophageal cancer epithelial–
mesenchymal transition. This combined therapeutic effect on esophageal cancer epithelial–mesenchymal transi-
tion was associated with upregulation of E-cadherin protein expression. (J Thorac Cardiovasc Surg
2010;139:1224-32)Supplemental material is available online.
Esophageal cancer represents a significant challenge to the
thoracic surgical community, because most patients are seen
with advanced stage disease. This is in large part due to the de-
velopment of early nodal or distant metastases. Despite ad-
vances in the staging of esophageal cancer, patients continue
to be seen with advanced stage disease because of the lack
of any screening biomarkers. Therapies aimed at inhibitinge Department of Surgery, University of Virginia, Charlottesville, Va.
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The Journal of Thoracic and Cardiovascular Surthe metastatic movement of esophageal cancer thus need to
be explored as an addition to the current tumoricidal therapies.
Metastatic progression is thought to be initiated by the
process of epithelial–mesenchymal transition (EMT), which
is characterized by epithelial cells assuming a mesenchymal
phenotype, thus allowing decreased cell adhesion, increased
motility, and increased proliferation. The cytokine trans-
forming growth factor b (TGF-b) has been shown to be
a key effector of EMT during cancer invasion and metasta-
sis.1,2 Regulation of EMT is governed by a number of
different genes, including metastasis suppressor genes,
such as the gene for E-cadherin (CDH1).3
Our laboratory has previously shown that combined use
of histone deacetylase (HDAC) and proteasome inhibition
is effective in the treatment of non–small cell lung cancer
cell lines.4 In light of these findings, a phase I clinical trial
with this combined molecular therapy for patients with
non–small cell lung cancer is underway at our institution.
Previous studies have demonstrated that HDAC inhibition
suppresses TGF-b–mediated EMT in human renal epithelial
cells.5 Other groups have shown that proteasome inhibition
blocks TGF-b–mediated EMT in human lens epithelium.6gery c May 2010
Abbreviations and Acronyms
ARHGDIB ¼ Rho guanosine diphosphate
dissociation inhibitor b gene
BRMS1 ¼ breast cancer metastasis suppressor
1 gene
CDH1 ¼ gene for E-cadherin
EMT ¼ epithelial–mesenchymal transition
HDAC ¼ histone deacetylase
GAPDH ¼ gene for glyceraldehyde-3-phosphate
dehydrogenase
KISS1 ¼ KiSS-1 metastasis-suppressor gene
NME1 ¼ protein (NM23A) expressed in
nonmetastatic cells 1
PCR ¼ polymerase chain reaction
TGF-b ¼ transforming growth factor b
TNF-a ¼ tumor necrosis factor a
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combined use of these molecularly targeted therapies would
decrease EMT in human esophageal cancer.
This study used a cell culture model of esophageal cancer
EMT to investigate the ability of suberoylanilide hydroxa-
mic acid (vorinostat), an HDAC inhibitor, and bortezomib,
a proteasome inhibitor, to prevent invasion and EMT. To
evaluate these chemotherapeutic agents, we used TGF-b to
induce EMT and tumor necrosis factor a (TNF-a) to mimic
the proinflammatory peritumoral stromal environment.MATERIALS AND METHODS
Cell Culture, Surgical Specimens, and Reagents
Human esophageal cancer (TE2 squamous carcinoma and SKGT4 ade-
nocarcinoma) were kindly provided by Dr Dao M. Nguyen (Miami, Fla).
TE2 cell lines were grown in Roswell Park Memorial Institute medium
1640 with high glucose, 10% fetal bovine serum, and 1% antibiotics.
SKGT4 cell lines were grown in Dulbecco modified Eagle medium with
high glucose, 10% fetal bovine serum, and 1% antibiotics. Vorinostat
was from Biomol (Enzo Life Sciences International, Inc, Plymouth Meet-
ing, Pa). Bortezomib was kindly provided by Millennium Pharmaceuticals
(Millennium Pharmaceuticals, Inc, Cambridge, Mass). TNF-a and TGF-
b were purchased from Sigma Pharmaceuticals (Sigma Pharmaceuticals,
LLC, Monticello, Iowa).
Plasmid Construction
The CDH1 promoter reporter plasmid (EcadLuc) was created by
isolating complementary DNA from human NL20 cells and was cloned
by polymerase chain reaction (PCR, primers 50-GGAAGATCTAGCCAC
CGGCGGGGCTGGG-30 forward and 50-CCCAAGCTTCCGGGTGCG
GTCGGGTCGG-30 reverse) and inserted into pGL3 vector (Promega
Corporation, Madison, Wis) with the restriction enzymes BglIII and HindIII
(New England Biolabs Inc, Beverly, Mass).Transfection and Luciferase Reporter Assays
Esophageal cancer cell lines at 50% to 60% confluence were transiently
transfected with the CDH1 promoter–luciferase construct with theThe Journal of Thoracic and CarPolyFect reagent (QIAGEN Inc, Valencia, Calif) according to manufacturer
recommendations. Luciferase reporter activity assays were performed as
previously described.7 b-Galactosidase activities were analyzed as a control
for the efficiency of transfection. Luminescence was normalized to protein
concentrations. Transfection data are reported as expressions relative to the
control treatment group. Transfection studies were carried out in triplicate.Metastasis Suppressor Gene Expression
Total RNA was extracted with TRIzol (Invitrogen Corporation,
Carlsbad, Calif) according to the manufacturer protocol. In brief, 106 cells
were lysed with 1 mL TRIzol, and the proteins were separated by chloro-
form. RNA was precipitated with isopropanol, and complementary DNA
was synthesized with an Advantage RT for PCR enzyme kit (Clontech
Laboratories, Inc, Mountain View, Calif). Metastasis suppressor gene
expressions of CDH1, breast cancer metastasis suppressor 1 gene
(BRMS1), the gene for protein (NM23A) expressed in nonmetastatic cells
1 (NME1), Rho guanosine diphosphate dissociation inhibitor b gene
(ARHGDIB), the CD44 gene, and the KiSS-1 metastasis-suppressor gene
(KISS1) were determined by quantitative reverse transcriptase PCR (Bio-
Rad iQ5; Bio-Rad Laboratories, Inc, Hercules, Calif). The human primers
are shown in Table 1. The expressions of the genes of interest were normal-
ized to an endogenous reference gene for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). Relative gene expressions were calculated as
previously described.8Treatment Groups
The dosages of vorinostat and bortezomib were based on previously
published studies.4 Treatment groups used for the study were as follows:
(1) control, no treatment; (2) TNF-a (20 ng/mL) and TGF-b (2 ng/mL);
(3) TNF-a (20 ng/mL), TGF-b (2 ng/mL), and vorinostat (5 mmol/L);
(4) TNF-a (20 ng/mL), TGF-b (2 ng/mL), and bortezomib (50 nmol/L);
and (5) TNF-a (20 ng/mL), TGF-b (2 ng/mL), vorinostat (5 mmol/L), and
bortezomib (50 nmol/L).Cell Death Assay
Cell death during and after treatment was measured with trypan blue.
After 24 hours of treatment, cells were trypsinized, stained with 0.4%
trypan blue, and counted. After quantification of cell death, the cells were
replated for 48 hours without treatment to determine delayed cell death; after
this, cell death was again quantified with trypan blue.
Two-Dimensional Invasion Assay
Two-dimensional invasion assays were conducted as previously
described.9 Migration and invasion were assessed with commercially
available Boyden chambers (BD Biosciences, San Jose, Calif) according to
manufacturer protocol. After the addition of cells, the chambers were
incubated at 37C for 48 hours. The percentage of invasion was calculated
by dividing the number of invading cells by the number of migrating cells.
The invasion percentage was then normalized to 1 to obtain an invasion index
with an untreated cell population. Experiments were conducted in triplicate.
Because both bortezomib and vorinostat have known effects on
cell growth inhibition, we sought to control for effects on cell growth to
determine the true effects of the combined therapy on cancer cell invasion.
All cells were recounted, and viability was reassessed before placement into
the invasion chambers for all the 2-dimensional assays. We were thus able
to control for cell growth inhibition, because the same number of viable cells
was placed into each invasion chamber.Morphometric Assay
SKGT4 cells were plated at a density of 1000 cells/well in 48-well tissue
culture plates. After 48-hour cell equilibration in Dulbecco modified Eaglediovascular Surgery c Volume 139, Number 5 1225
TABLE 1. Quantitative polymerase chain reaction primers
Gene Forward (50–30) Reverse (50–30)
CDH1 TTCCTCCCAATACATCTCCCTTCACAGCAG CGAAGAAACAGCAAGAGCAGCAGAATCAGA
BRMS1 TGCAGCGGAGCCTCAAG TCACATCCAGACAGAAGCCCT
ARHGDIB CCAACTCCTGCCAGATCATT TCCCTTGTGCTGCTACATTG
NME1 AGCGTTTTGAGCAGAAAGGA GGCCCTGAGTGCATGTATTT
CD44 TCAGAGGAGTAGGAGAGAGGAAAC GAAAAGTCAAAGTAACAATAACAGTGG
KISS1 TGGGGAATTCTAGACCCACA CAGTAGCAGCTGGCTTCCTC
GAPDH CCAGTGCAAAGAGCCCAAAC GCACGGACACTCACAATGTTC
CDH1, Gene for E-cadherin; BRMS1, breast cancer metastasis suppressor 1 gene; ARHGDIB, Rho guanosine diphosphate dissociation inhibitor b gene; NME1, protein (NM23A)
expressed in nonmetastatic cells 1, KISS1, KiSS-1 metastasis-suppressor gene; GAPDH, gene for glyceraldehyde-3-phosphate dehydrogenase.
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Cells were then fixed and stained according to the protocol described for
the 2-dimensional invasion assay. Cell were then photographed with light
microscopy.
Three-Dimensional Invasion Assay and E-Cadherin
Blocking Antibody Treatment
Tumor spheres were created with the method previously published
by our group.9 Briefly, TE2 and SKGT4 cells were diluted to 8 3 105
cells/mL, and drops of the cell suspension (15 mL) were placed onto the
lids of 100-mm dishes, which were inverted over dishes containing
phosphate-buffered saline solution. The hanging drops were placed into
a 37C incubator for 3 days, after which the spheroids of both cell lines
were transferred and implanted into 3-dimensional collagen I gels including
2.5-mg/mL rat collagen I (R&D Systems, Inc, Minneapolis, Minn) and
overlaid with 2 mL Roswell Park Memorial Institute or Dulbecco modified
Eagle medium containing the previously noted treatment groups. This
method is a reproducible, well-accepted approach to determining invasive
potential of tumor cells.10 Tumor spheres were treated with E-cadherin–
blocking antibody (Sigma DECMA-1 1:100; Sigma Pharmaceuticals).11
Western Blot
Western blots were performed according to standard procedures.4 Mouse
primary antibodies to E-cadherin (BD Biosciences) and b-actin (Santa Cruz
Biotechnology, Inc, Santa Cruz, Calif) were used. A 50-mg portion of
protein lysate for each treatment group was separated with 10% sodium
dodecyl sulfate polyacrylamide gel electrophoresis. After transfer, nitrocel-
lulose membranes (Bio-Rad) were probed with primary antibodies at
a 1:1,000 dilution and secondary antibodies (Promega) at a 1:5,000 dilution
in blocking solution. Proteins were visualized with enhanced chemilumines-
cent substrate (Pierce; Thermo Fisher Scientific Inc, Rockford, Ill).
Statistical Analysis
Results were expressed as mean  SD. Comparisons between treatment
groups were made with the Student t testRESULTS
Therapy with vorinostat, bortezomib, or both combined
resulted in significantly decreased tumor cell invasion after
the induction of EMT in both esophageal squamous carci-
noma and adenocarcinoma histologic types (Figure 1).
Furthermore, combined treatment with vorinostat and borte-
zomib significantly decreased invasion of esophageal cancer
cells relative to bortezomib therapy alone, and the difference
approached significance versus vorinostat therapy alone
(P ¼ .07).1226 The Journal of Thoracic and Cardiovascular SurTo assess whether this reduction in cell invasion was
primarily related to increased cell death caused by these
molecularly targeted agents, we next performed cell death
assays. As shown in Figure 2, cell death was noted in
10% to 40% of cells 24 hours after treatment. Further
assessment of cell death at 72 hours after treatment was
performed to ascertain the contribution of delayed cell death.
At 72 hours of treatment, there was only an additional 5%
cell death from the original 24-hour assessment. According
to this assay, the use of vorinostat, bortezomib, or both thus
induces only modest cell death within the first 24 hours of
treatment, with most esophageal cancer cells remaining
viable afterward.
To investigate further the mechanism for decreased cell
invasion with treatment with vorinostat, bortezomib, or
both, we performed quantitative reverse transcriptase PCR
for known metastatic suppressor genes and markers of
EMT (Figures 3 and E1). With the esophageal adenocarci-
noma cell line SKGT4, we demonstrated the induction of
EMT by a robust increase in the transcription of N-cadherin
and vimentin and increased spindle cell morphology associ-
ated with TNF-a and TGF-b (Figure E1). Interestingly,
we found that the predominant restoration of the epithelial
phenotype after TNF-a and TGF-b exposure was related
more to the effects of bortezomib and less to those of
vorinostat (Figures 1, A, and E1).
In light of the evidence supporting EMT in the metastatic
process, we assayed metastatic suppressor gene expression
as a correlate of the role of these 2 molecularly targeted ther-
apies in augmenting EMT. We found that CDH1 transcrip-
tion was upregulated 80-fold in squamous carcinoma and
4-fold in adenocarcinoma after treatment with both vorino-
stat and bortezomib relative to the group with TNF-a and
TGF-b treatment alone. Combined therapy also resulted in
significant increases in NME1 and ARHGDIB transcriptions
in squamous carcinoma but not esophageal adenocarcinoma.
No significant differences in transcription with combined
therapy were noted for BRMS1, CD44, and KISS1. Thus
only CDH1 transcription was robustly increased in both
squamous cell carcinoma and adenocarcinoma esophageal
cancer histologic types after exposure to vorinostat and
bortezomib.gery c May 2010
FIGURE 1. Two-dimensional esophageal cancer invasion decreased with vorinostat and bortezomib (Bortez) treatment after induction of epithelial–
mesenchymal transition. A, Treatment with vorinostat and bortezomib in esophageal squamous carcinoma (TE2) resulted in significantly decreased cell
invasion. B, Treatment with vorinostat and bortezomib in esophageal adenocarcinoma (SKGT4) resulted in significantly decreased cell invasion. Crosshatch
denotes P<.05 for control versus for tumor necrosis factor (TNF) and transforming growth factor (TGF). Asterisk denotes P<.01 for treatment group versus
tumor necrosis factor and transforming growth factor. Plus sign denotes P<.05 for bortezomib treatment group versus combined vorinostat and bortezomib
treatment group.
FIGURE 2. Combined vorinostat and bortezomib (Bortez) treatment induced modest esophageal cancer cell death in both squamous carcinoma (TE2)
and adenocarcinoma (SKGT4) histologic subtypes after 24 hours of treatment.
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FIGURE 3. Metastasis suppressor gene transcription (CDH1, gene for E-cadherin; BRMS1, breast cancer metastasis suppressor 1 gene; NME1, gene for
NM23A; ARHGDIB, gene for Rho guanosine diphosphate dissociation inhibitor [RhoGDI2], CD44; KISS1, gene for KiSS-1) after induction of epithe-
lial-mesenchymal transition and with treatment with vorinostat, bortezomib (Bortez), or both. E-cadherin transcription was significantly upregulated in
both esophageal squamous (TE2) and adenocarcinoma cell lines (SKGT4) after combined treatment of vorinostat and bortezomib. In squamous esophageal
cancer, combined vorinostat and bortezomib resulted in increased nm23 and RhoGDI2 transcription. Asterisk denotes P< .01 for treatment group versus
tumor necrosis factor and transforming growth factor. Plus sign denotes P<.05 for bortezomib treatment versus combined vorinostat and bortezomib treat-
ment. Crosshatch denotes P< .05 for vorinostat treatment versus combined vorinostat and bortezomib treatment. Caret denotes P<.05 for control versus
tumor necrosis factor (TNF) and transforming growth factor (TGF). mRNA- Messenger RNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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scription was regulated by increases in activity of the
CDH1 promoter. Figure 4 illustrates that combined therapy
resulted in increased CDH1 promoter activity in squamous
carcinoma relative to control and single-agent therapy. In
esophageal adenocarcinoma, combined therapy resulted in
significantly higher CDH1 promoter activity relative to the
TNF-a and TGF-b group, but the activity was not signifi-
cantly different from that seen with either single-agent
therapy. These observations suggest that increases in
CDH1 transcription after combined therapy occurs at the
promoter level, particularly for esophageal squamous cell
cancer histologic type.
Having found CDH1 transcription and promoter activity
to be upregulated after combined therapy, we next demon-
strated that protein levels of E-cadherin were enhanced after
combined therapy (Figure 5). With the TE2 squamous cell
carcinoma line, which has very low basal levels of E-cad-
herin, there was a very modest re-expression of E-cadherin
protein with either vorinostat or bortezomib alone but
a robust re-expression of E-cadherin protein with combined
therapy.
Finally, to ascertain the specific role of E-cadherin in
modulating the anti-EMT response generated by combined
HDAC and proteasome inhibition, 3-dimensional cellFIGURE 4. E-cadherin gene promoter activity was increased with combined
carcinoma (TE2) and adenocarcinoma (SKGT4). Plus sign denotes P<.05 for v
P< .05 for bortezomib treatment versus combined vorinostat and bortezomib t
necrosis factor and transforming growth factor. Caret denotes P< .05 for co
(TGF). RLU, Relative luminescence units; Bgal, b-galactosidase.
The Journal of Thoracic and Carcultures were created. As shown in Figure 6, TNF-a and
TGF-b–treated cells in 3-dimensional culture invaded and
migrated within a collagen matrix, and treatment with com-
bined vorinostat and bortezomib abolished this process
of tumor cell invasion. Treatment of the tumor spheres
subjected to combined therapy with a specific E-cadherin–
blocking antibody resulted in a dramatic increase in cell
invasion. This strongly suggests that E-cadherin is a primary
mediator of vorinostat and bortezomib–induced abolition of
EMT in esophageal cancer cells.
DISCUSSION
This study demonstrates the potential utility of combined
HDAC and proteasome inhibition in attenuating esophageal
cancer EMT and suggests that E-cadherin re-expression
found with treatment may be critical for metastatic inhibi-
tion. E-cadherin is a 120-kDa transmembrane protein critical
for maintaining cell–cell interaction. Loss of E-cadherin has
been demonstrated in numerous forms of cancer, including
esophageal cancer.12 Furthermore, E-cadherin downregula-
tion has been found to be a hallmark of the initiation of
EMT.3
The association between decreased E-cadherin expression
and esophageal cancer is well documented. A recent review
of 187 articles evaluating markers of squamous esophagealtreatment with vorinostat and bortezomib in both esophageal squamous
orinostat treatment versus bortezomib (Bort) treatment. Crosshatch denotes
reatment. Asterisk denotes P< .02 for given treatment group versus tumor
ntrol versus tumor necrosis factor (TNF) and transforming growth factor
diovascular Surgery c Volume 139, Number 5 1229
FIGURE 5. Combined treatment with vorinostat (Vorino) and bortezomib
(Bort) induces protein expression of E-cadherin in esophageal cancer (TE2)
cells. TNF, Tumor necrosis factor; TGF, transforming growth factor.
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potential markers’’ for the prediction of survival in patients
with esophageal cancer.13 Imamura and colleagues14 dem-
onstrated that reduced tumor E-cadherin was associated
with poor prognosis in 416 patients with esophageal cancer.
In another study of 105 patients, reduced tumor E-cadherin
correlated with poorer survival, grade, and clinical stage.15
Additionally, that study found that reduced intratumoral E-
cadherin was associated with increased incidence of lymph
node and venous metastases.15 With respect to esophagealFIGURE6. Three-dimensional esophageal cancer metastasis decreased with com
blocking antibody (E-cad anti) to tumor cells treated with vorinostat and bortezo
adenocarcinoma (SKGT4, B) cell lines.
1230 The Journal of Thoracic and Cardiovascular Suradenocarcinoma, intratumoral E-cadherin was found in
75% of 59 esophageal adenocarcinoma specimens, and
patients with reduced E-cadherin had a significantly worse
prognosis, with a hazard ratio of 3.3.16
Our laboratory has previously demonstrated efficacy of
the combined molecularly targeted therapy of bortezomib
and vorinostat in non–small cell lung cancer.4 Previous stud-
ies have demonstrated that the tested concentrations of both
vorinostat and bortezomib are safely achievable in human
subjects17,18; however, no studies have investigated this
combination therapy in the treatment of esophageal cancer.
We focused our investigation on the potential properties
of these drugs to inhibit EMT because of evidence in
the literature supporting the important role of EMT in the
metastatic process. We therefore sought to determine the
expression patterns of known metastatic suppressor genes,
including CDH1, BRMS1, NME1, ARHGDIB, KISS1, and
CD44. This use of histone deacetylase and proteasome
inhibition in the model was based on previous work with
this drug combination with non–small cell lung cancer cell
lines and pilot studies from our laboratory with esophageal
cancer cell lines.4 Yoshikawa and colleagues5 found that
HDAC inhibition suppressed TGF-b1–induced EMT re-
sponsible for tubulointerstitial fibrosis of the kidney and
that this suppression of EMT was associated with increased
E-cadherin transcription. In addition, HDAC inhibition was
found to suppress metastasis in pancreatic cancer.19bined vorinostat (V) and bortezomib (B) treatment. Addition of E-cadherin–
mib induced increased metastasis in both squamous carcinoma (TE2, A) and
gery c May 2010
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to inhibit tumor growth and angiogenesis in human squa-
mous cancer cell lines.20 Saitoh and colleagues21 also dem-
onstrated that bortezomib stabilizes cell surface E-cadherin
during TGF-b–induced EMT. In contrast to our work, that
study demonstrated no significant decrease in cancer cell
mobility after bortezomib treatment. This discrepancy be-
tween our findings and those of Saitoh and colleagues21
could be explained by several observations. First, the studies
used different cell lines and proteasome inhibitors. Second,
Saitoh and colleagues’ work21 used TGF-b3, whereas our
model used TGF-b1. Although these isoforms recognize
the same receptors, it is known that they have different
and sometimes opposing biologic functions in certain
models.22 Third, our study used 2 invasion assays to quan-
tify cell mobility, whereas Saitoh and colleagues’ study21
used wound healing assays to characterize mobility.
Recent work may provide some insight into the mecha-
nism by which HDAC inhibition and proteasome inhibition
increase E-cadherin at the promoter level. Von Burstin and
colleagues19 demonstrated that inactivation of CDH1 ex-
pression in metastatic pancreatic cancer cell lines is medi-
ated through a repressor complex containing HDAC1,
HDAC2, and SNAIL. Furthermore, that study showed that
TGF-b–mediated CDH1 repression is dependent on
HDAC activity. Additionally, knowing that SNAIL binding
sites are present on the CDH1 promoter, it is possible that
bortezomib inhibits SNAIL, thereby relieving the transcrip-
tional repression on the CDH1 promoter.23 Finally, CDH1
promoter activity may also be regulated by methylation
through histone modification by means of methyltransferase
genes, such as EZH1 and EZH2.24
There has been limited work investigating this combina-
tion therapy for the treatment of cancer. Recently, combined
vorinostat and bortezomib therapy has been found to prevent
synergistically proliferation of colorectal cancer cell lines.25
Previously published work and the results of this study sug-
gest that one mechanism through which this combined ther-
apy inhibits metastasis may be synergistic re-expression of
CDH1.
There are several limitations to this study. First, we used
only 2 human esophageal cancer cell lines, 1 squamous car-
cinoma and 1 adenocarcinoma. Thus investigation of other
cell lines may be advantageous. Second, this study investi-
gated EMT with only TGF-b and TNF-b. In patients with
esophageal cancer metastasis, however, a multitude of cyto-
kines, transcription factors, and proteins likely interact with
each other to initiate metastasis. This model cannot account
for all these other factors potentially involved in EMT and
metastasis. Clearly, animals studies in which these esopha-
geal cancer cell lines undergo EMT and are subsequently
evaluated for metastatic lesions after this molecularly tar-
geted therapy would be useful in establishing the validity
of this mechanism in vivo.The Journal of Thoracic and CarIn conclusion, combined HDAC and proteasome inhibi-
tion attenuates esophageal cancer EMT by upregulating E-
cadherin expression in human esophageal cancer cell lines.
This study highlights the importance of E-cadherin in mod-
ulating EMT in esophageal cancer and provides insight into
the importance of restoring intratumoral E-cadherin levels to
achieve maximal therapeutic efficacy when using these mo-
lecularly targeted therapies. Because of the dismal prognosis
for patients with esophageal cancer, further investigation of
this combined molecularly targeted therapy is warranted.References
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FIGURE E1. A, Morphologic analysis of SKGT4 cell line associated with treatment groups. Tumor necrosis factor a (TNF) and transforming growth factor
b (TGFb) treatment demonstrated increased mesenchymal cell morphology associated with induction of epithelial–mesenchymal transition. Treatment with
vorinostat, bortezomib (Bortez), or both (VþB) restored epithelial phenotype from mesenchymal phenotype. B, Real-time polymerase chain reaction demon-
strated significant upregulation of vimentin and N-cadherin after treatment with tumor necrosis factor a and transforming growth factor b. Asterisk denotes
P<.05 for control versus tumor necrosis factor a and transforming growth factor b. Crosshatch denotes P<.03 for control versus tumor necrosis factor a and
transforming growth factor b. mRNA, Messenger RNA; GAPDH, gene for glyceraldehyde-3-phosphate dehydrogenase.
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